INTRODUCTION
L ipopolysaccharide (lps) is a major structural component of the outer-membrane of gram-negative bacteria. It provides critical protection to host defenses and a permeability barrier to many antibiotics. UDP-3-O-(R-3hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) catalyzes the committed reaction step in the biosynthesis of lipid A, the membrane anchor of LPS. This enzyme is an attractive target for antibacterial drug discovery as it is conserved among important gram-negative pathogens, is essential for bacterial viability, and lacks a mammalian counterpart.
HTS. Such a screening platform, using as natural a biochemical system as possible, would scrutinize the entire ligand-binding pocket and perhaps identify novel chemotypes that may be missed using nonnative surrogate substrates. 11 We describe here a label-free method to characterize the enzymatic activity of bacterial LpxC using high-throughput mass spectrometry. An automated sample handling, purification, and injection system developed by BioTrove, Inc. (Woburn, MA) was used for a screening assay with enzyme kinetics comparable to those generated using the radiochemical technologies. 12 We have used this technology to identify LpxC inhibitors from a compound library of more than 700,000 small molecules arrayed as orthogonal mixtures. Hit compounds were confirmed using a fluorescence-based thermal stability shift assay, 13 generating K d values comparable to the biochemical IC 50 values. Finally, we show that the some hit compounds showed wholecell antimicrobial activity against a hypersensitive strain of Escherichia coli that has reduced LpxC activity. We conclude that high-throughput mass spectrometry can augment traditional platforms for successfully screening targets involving complex substrates or subtle enzymatic modifications.
MATERIALS AND METHODS

Materials
All general biochemical reagents were obtained from Sigma-Aldrich (St. Louis, MO) and Fisher Scientific (Pittsburgh, PA). The LpxC substrate, UDP-3-O-(R-3-hydroxy-myristoyl)-N-acetyl-glucosamine, was obtained from the Alberta Research Council (Alberta, Canada). The product of the LpxC reaction, UDP-3-O-(R-hydroxymyristoyl)-glucosamine, was purified following enzymatic reaction. UDP-3-O-(R-3-hydroxymyristoyl)-GlcNAc (2 mg/mL) was combined with 0.2 mg/mL purified LpxC (see below) in a reaction containing 50 mM HEPES (pH 7.3), 150 mM NaCl, 2 mM dithiothreitol (DTT), and 10% glycerol. After incubation at room temperature for 40 min, the reaction was applied to a YMC-Pack ODS-A 100 × 10-mm high-performance liquid chromatography (HPLC) column, then fractionated using a linear gradient of 0% to 58% acetonitrile in water plus 20 mM triethylamine-phosphoric acid (pH 7.0) at 4 mL/min. Fractions containing the LpxC product were collected, lyophilized, reconstituted in water, and stored at -80 °C. The procedure resulted in a yield of approximately 80 mg of UDP-3-O-(R-3-hydroxymyristoyl)-Glc. Product identity was confirmed with liquid chromatography/mass spectrometry (LC/MS) and by UV spectroscopy.
Bacterial strains, plasmids, enzymes, and chemicals. E. coli D21 (F-, proA23, lac-28, tsx-81, trp-30, his-51, rpsL173(strR), ampCp-1) and the isogenic lpxc mutant E. coli D22 (F-, lpxC101, proA23, lac-28, tsx-81, trp-30, his-51, tufA1, rpsL173(strR), ampCp-1) were purchased from the E. coli Genetic Stock Center (CGSC) at Yale University (New Haven, CT). The E. coli T7 expression strain BL21 (DE3) was purchased from Invitrogen (Carlsbad, CA). Other bacterial strains were obtained from the American Type Culture Collection (ATCC). Bacteria were grown in Mueller Hinton broth or Luria broth at 37 °C unless otherwise specified.
Construction of lpxC expression plasmid. The lpxC wildtype gene was PCR amplified from E. coli ATCC27325 genomic DNA prepared using the Wizard  DNA Purification System (Promega, Madison, WI). The 5' end PCR primer overlapped the ATG start codon and contained an NdeI restriction site, and the 3' end primer overlapped the stop codon and contained an XhoI restriction site. The NdeI-XhoI digested PCR fragment was cloned into the pET29a T7 expression plasmid, purchased from Novagen (Madison, WI). The plasmid DNA was sequenced by Genewiz, Inc. (South Plainfield, NJ) to verify the wild-type sequence. The pET29a-EclpxC expression plasmid was transformed into E. coli BL21 (DE3) using standard techniques.
Expression and purification of E. coli LpxC protein.
For recombinant protein purification, 12-L cultures of E. coli Bl21 (DE3) pET29a/LpxC were grown in Miller's Luria-Bertani (LB) medium supplemented with 30 mg/mL kanamycin. Following fermentation at 37 °C to 0.6 A 540nm , cultures were supplemented with 10 mM ZnSO 4 and then treated with 1 mM IPTG. Following protein induction at 30 °C for 2 h, cells were collected by centrifugation; resuspended (120 mL per 2-L cell pellet) in 25 mM HEPES (pH 7.3), 100 mM ZnSO 4 , 2 mM DTT, and 5% glycerol (buffer A); and lysed by passage through a microfluidizer.
All subsequent steps were carried out on ice or at 4 °C. The cell-free lysate was adjusted to 50% (w/v) with ammonium sulfate and then stirred for 1 h. The protein pellet was then suspended in 50 mL of 25 mM HEPES (pH 7.3), 2 mM DTT, and 5% glycerol (buffer B) and applied to a Q-Sepharose column (Amersham Biosciences [Fairfield, CT], HL 26/10) equilibrated in buffer B. LpxC was eluted at 5 mL/min using a 1000-mL linear gradient of 0 to 0.5 M NaCl in buffer B. Fractions containing LpxC were concentrated and then applied to a preparative Sephadex G-75 column (Amersham Biosciences, Hiprep 26/60) and eluted in 1 column volume of 25 mM HEPES (pH 7.3), 150 mM NaCl, 2 mM DTT, and 5% glycerol at 4 mL/min. The fractions containing LpxC were pooled and protein concentration was determined by UV spectroscopy using a molar extinction coefficient of 22340 M -1 cm -1 . This process typically yields 3 to 5 mg of monomer per liter with purity of >90%. Solutions containing LpxC (at 0.85 mg/mL) were aliquoted and stored at -80 °C until use.
HTS.
To expedite screening efficiency, we formatted the compound library using an 8 × 8 orthogonal mixing protocol, with each compound appearing twice on each plate in separate mixtures. 14 Assay plates were prepared containing 10 mL test compound mixture (8 compounds per pool, 2-mg/mL compound concentrations). Substrate, UDP-3-O-(R-3-hydroxy-myristoyl)-N-acetyl-glucosamine, was first added to wells, adding 20 mL (final assay concentration 1 mM); the reaction was initiated by the addition of LpxC enzyme (20 mL; final assay concentration 0.2 nM) in buffer containing 25 mM HEPES (pH 7.3), 150 mM NaCl, 2 mM DTT, and 0.01% bovine serum albumin using a Matrix PlateMate Plus 384-channel automated pipetting system (Thermo Fisher Scientific, Hudson, NH). After incubation at room temperature for 60 min, reactions were stopped by the addition of 0.25 N HCl (20 mL) and the plates sealed and cooled to -80 °C. The frozen plates were then sent on dry ice to Biotrove, Inc. for analysis using the RapidFire ultra-highthroughput mass spectrometry system, consisting of a proprietary computer-controlled fluidic robot interfaced with a Sciex API-4000 triple-quadrupole mass spectrometer.
For RapidFire analysis, an aliquot (20 mL) of the thawed assay sample was withdrawn from each well of the 384-well microplate (250-ms aspiration), of which 10 mL was then applied to a proprietary solid-phase extraction cartridge under conditions designed to retain analytes of interest. Following a 2-s aqueous wash to remove components in the reaction mixture incompatible with mass spectrometry, analytes were eluted in 2.5 s using (1:1:2) acetonitrile/acetone/ddH 2 O containing 5 mM ammonium acetate, then analyzed by triple-quadrupole mass spectrometry (total sample-to-sample cycle time 5.25 s; plate handling increased processing time to 42.5 min per 384-well plate, or 6.6 s per sample).
Mass spectrometry was carried out using electrospray ionization in the negative ion mode. Daughter ion peaks representing detected substrate (parent Q1 mass = 832.3 amu, daughter Q3 mass = 385.2 amu, collision energy = -50 eV, dwell time = 100 ms) and product (parent Q1 mass = 790.4 amu, daughter Q3 mass = 385.2 amu, potential [DP] = -150 V, collision energy [CE] = -50 eV, dwell time = 100 ms) were identified using a multiple-reaction monitoring protocol and the percentage of substrate converted to product reported. The purification and mass spectrometry analysis steps described above were performed in a serial manner, eliminating the need for upfront sample preparation or purification. Buffer washes between samples (each of 500 ms) minimized carryover contamination. Hits were identified as compounds that showed ≥50% inhibition of total substrate conversion in both pools. Pools showing ≥50% inhibition in only 1 well were identified as false positives and were not progressed. The inhibitory activity of individual compounds identified as hits from the orthogonal mixtures was confirmed in separate assays, carried out as ranging 5-point IC 50 determinations run on 2 separate days. The IC 50 value from each run was approximated by log-linear interpolation to 50%I using the 2 points positioned above and below the 50% inhibition value-this system eliminated scaling issues associated with compound insolubility at high concentrations.
Data tracking and analysis. Data from screening experiments were tabulated using the Oracle-based proprietary data management system developed by the Schering-Plough Research Institute, New Lead Discovery. Integration of data with specific compounds is managed by the system through tracking of compound transfers to and from barcoded plates. The IC 50 value was approximated as the mean between 2 points positioned above and below the 50% inhibition value-this system eliminated scaling issues associated with compound insolubility at high concentrations. Data from nonscreening experiments were analyzed using Prism 2.0b (GraphPad, San Diego, CA), using sigmoidal dose-response curve-fitting algorithms (variable slopes, no constraints) provided by the vendor. Assay robustness was calculated as described. 15 Each assay plate included 16 wells used for the Z' factor calculation, 8 as a positive control for the assay and 8 as a negative control. Campaign robustness was calculated as the median Z' factor from the more than 500 plates evaluated as part of the campaign.
Biophysical measurement of binding using thermal stability shift assay. The ability of a bound ligand to stabilize a target protein from thermal denaturation was used to estimate the dissociation constant (K d ) between LpxC and selected test compounds. 13 Purified LpxC (20 mL of 4 mM) was mixed with ~10 to 50 mM of test compound in 25 mM HEPES (pH 7.3) buffer containing 150 mM NaCl, 2 mM DTT, and Sypro Orange (5×; Molecular Probes, Inc., Eugene, OR) in a 96-well PCR plate. The plate was strip-sealed and then placed in a real-time thermocycler (Chromo4, Bio-Rad, Hercules, CA). The plate was then incubated for 45 min at increasing temperatures from room temperature to 100 °C in increments of 0.5 °C. Increased fluorescent intensities with Sypro Orange binding to hydrophobic cavities exposed upon denaturation were measured. The concentrationdependent melting point shifts were subjected to nonlinear regression analysis to derive a temperature-dependent fluorescence (TdF) K d values, using algorithms derived from previous literature. 13 The calculation assumes average enthalpy change of binding at -7 kcal/mol, with an assigned uncertainty of approximately 50%.
Antibacterial susceptibility testing. Whole-cell antimicrobial activity assays were performed using the Clinical and Laboratory Standards Institute (CLSI) approved method for antimicrobial susceptibility testing. Bacterial strains used in this investigation were E. coli D21 (lpxC + ) and D22 (lpxC101) as previously described. 16 Cultures of test organisms were grown overnight and diluted to 5 × 10 5 CFU/mL in cation-adjusted Mueller Hinton Broth. Test compounds were added in 2-fold serial dilutions to wells of 96-well microplates. Diluted culture, 100 mL, was then added to the sample wells. Plates were incubated for 16 h at 37 °C. Minimum inhibitory concentration (MIC) values were determined as the lowest concentration of compound that completely inhibited visual bacterial growth.
RESULTS
Assay development first involved establishment of conditions for mass spectrometry for component ion visualization.
Purified aliquots of UDP-3-O-(R-3-hydroxy-myristoyl)-N-acetylglucosamine (substrate) and UDP-3-O-(R-hydroxymyristoyl)glucosamine (product) were subjected to analysis using a Sciex model API-4000 electrospray mass spectrometer (Applied Biosystems, Foster City, CA). Figure 1A shows an expected mass species for substrate at 832.3 amu and for the product at 789 amu-the ions are 1 atomic mass unit lower than the theoretical mass of the analytes, due to proton removal for molecules with a net (-1) charge. Also note that 13 C isotope peaks are seen as shoulders at 1 and 2 mass units larger than the parent ion mass, confirming that the analytes are in the net (-1) charge form. The technique of triple-quadrupole mass spectrometry was then used to discriminate the desired reaction components from contaminating mass species based on molecular mass, ionization mode (positive or negative), and fragmentation pattern upon collision with molecules of inert N 2 gas; a fragment at 385.2 mass units was used to quantify the substrate (Fig. 1B) and product (Fig. 1C) in the multiple-reaction monitoring (MRM) mode. MRM requires that the quantitated substrate and product species have the correct M-H (molecular mass less 1 proton) mass and the correct fragment ion size following collision with a molecule of nitrogen-the chance that an isobaric contaminant species shares both the M-H mass and the same fragment ion size is small, decreasing the chance of quantitating spurious species. Using these selected fragments, conditions were identified to quantify the analyte peaks from the complex reaction mixture.
Seven-point serial dilutions of substrate and product were made in LpxC assay buffer containing 1 N HCl, used to stop the enzymatic reaction. Samples were subjected to analysis using the Biotrove RapidFire platform. 12 The instrument applies 10 mL of test sample to a proprietary solid-phase extraction cartridge under conditions designed to retain analytes of interest, allowing assay components to be washed free with HPLC grade ddH 2 O. The analytes were then extracted using (1:1:2) acetonitrile/acetone/ddH 2 O containing 5 mM ammonium acetate and then analyzed. Figure 2 shows that the analyte signal gives a linear response over concentrations from 156 nM to 10 mM, with the Z' factor for analysis of 10 mL of 156-nM samples (1.6 picomoles of analyte analyzed) reaching 0.88. Because the substrate and product of the LpxC reaction were similar (differ by a single acetylation), fragmentation and ionization efficiencies for the 2 compounds are essentially within the coefficient of variation of the analysis. Therefore, the LpxC substrate and product signals could be directly compared for calculation of the percentage conversion. Were this not the case, and the substrate and product had different ionization efficiencies, only an apparent conversion could be calculated. This can be accomplished by comparing changes in substrate and product to some internal standard species not affected by the target enzymology. Sample injections in Figure 2 were followed by injections containing assay buffer alone, showing no evidence of carryover from sample to sample.
LpxC mass spectrometry assay development
Enzymatic characterization of recombinant purified LpxC was performed to develop optimal assay conditions for inhibitor detection. The purified enzyme (2 nM) was incubated with 2.5 mM substrate in reaction containing 25 mM HEPES (pH 7.3), 150 mM NaCl, 2 mM DTT, 10% glycerol, and 0.01% bovine serum albumin. At specified times, triplicate reactions were terminated with the addition of 10% (v/v) 1 N HCl and then analyzed. Figure 3 shows that increased incubation time resulted in decreased substrate ion signal (Fig. 3A) and increased product ion signal (Fig. 3B) . Quantitation of the peak areas (Fig.  4A) shows a linear conversion of substrate to product through 60-min incubation with 0.5 nM enzyme. Analysis of assays with varied substrate concentration demonstrated standard saturation 2.0 to 3 mM. 1, 10 The reaction was inhibited by incubation with BB78485, a hydroxamate inhibitor, with an IC 50 of 2 mM (Fig.  4C) . The published IC 50 value with a low throughput assay was 0.2 mM 2 (note: the reported IC 50 for BB78485 was carried out following product hydrolysis to the 3-O-acyl ester in 0.2 N sodium hydroxide and then detected following reaction with o-phthaldialdehyde [OPA]-2-mercaptoethanol). The reaction was unaffected by changes in pH between pH 6 and 8 (data not shown) and was unaffected by addition of DMSO between 0% and 10% (Fig. 5 ).
Assay validation
Having shown that the high-throughput mass spectrometry can be used to measure LpxC activity and that the assay has some properties required to support screening (unaffected by DMSO, stable to minor changes in pH), we carried out several additional validation experiments: (1) the assay exhibited a linear decrease in activity with increasing glycerol, reaching 80% of activity at 10% glycerol; (2) reagents could be stored for 4 h at room temperature before analysis without affecting observed activity; (3) reactions could be flash frozen at -80 °C and then thawed before analysis without affecting observed activity. The final assay protocol, evaluated on 4 separate days using 48 wells/plate measuring total activity and 48 wells/plate measuring total inhibited activity, yielded an average Z' score of 0.75. This established the fully validated screening assay protocol. The reaction was initiated by adding 20 mL LpxC enzyme to compounds (10 mL) plus substrate (20 mL) using the Matrix PlateMate Plus 384-channel automated pipetting system (Thermo Fisher Scientific). After incubation for 60 min at room temperature, the reaction was terminated by addition of 20 mL 0.25 N HCl. The assay plates were sealed and then placed at -80 °C for a minimum of 2 h. The stabilized assay plates were then shipped on dry ice to BioTrove, Inc. for analysis. Fig. 4B ). This K m value compares favorably with the reported results with the native substrate of After 60 min at room temperature, the reaction was quenched and then analyzed as described. ♦, 0%; ■, 1%; □, 2%; x, 3%; x -, 4%; •, 6%; +, 8%; -, 10% DMSO.
Library screening for LpxC inhibitors
The optimized LpxC mass spectrometry assay was used to evaluate a random compound library for enzyme inhibitors. The compound library was arrayed in orthogonal pools, 14 with 8 compounds per mixture (each compound at 2 mg/mL). Orthogonal pairs were contained on the same assay plates; thus, each 384-well plate contained 1280 compounds plus validating standards and controls. Hits were identified as compounds that showed ≥50% inhibition in both pools; pools showing ≥50% inhibition in only 1 well were identified as false positives and excluded from further consideration. Figure 6 shows that the behavior of the screening assay throughout the campaign exhibited a median Z' factor of 0.74 for the entire screen. However, use of orthogonal mixtures of compounds was shown to depress the observed activity in all assay plates; the mean inhibition for inactive compounds in the screen was determined to be ~13% (Fig. 7A) . The robustness of the assay enabled us to select a significant collection of hits from the screen. Confirmation testing of the hits as 5-point dose-response curves starting at half-log above the screening concentration (Fig. 7B) showed a significant number of validated hits with IC 50 s below 1 mg/mL.
Confirmation testing using fluorescence-based thermal stability shift assay
To confirm that hits identified using high-throughput mass spectrometry bound to the target protein, we characterized the ability of the compounds to modulate the thermal stability of LpxC. 13 Test compounds (in a 96-well PCR plate) were mixed with purified LpxC in buffer containing Sypro Orange, an environmentally sensitive dye that fluoresces upon binding to a hydrophobic environment unmasked with protein thermal denaturation. Sealed plates were then placed in a real-time thermocycler and subjected to a 45-min incubation course from room temperature to 100 °C in 0.5 °C increments. Figure 8 shows that selected compounds identified in the mass spectrometry screen stabilize LpxC to thermal denaturation, shifting the observed melting curves to higher temperatures. The K d calculated from these binding experiments compares favorably with IC 50 values generated using the high-throughput mass spectrometry screening assay ( Table 1 ). These results confirm that the selected test compounds bind purified LpxC, and this binding is required for the observed change in enzymatic activity.
Validation of selected LpxC inhibitors in whole-cell antimicrobial activity assays
Compounds identified in this campaign were tested for antibacterial activity using standard CLSI methods (see Materials and Methods). Table 1 shows that 5 of 6 test compounds The optimized LpxC mass spectrometry assay was used to evaluate a random compound library for enzyme inhibitors. Wells containing 2% DMSO (total activity sample) or hydroxamate inhibitor (total inhibited sample) were used to calculate the Z' score for each assay plate. demonstrated biological activity versus E. coli D22, a hypersensitive strain that has reduced LpxC activity. The compounds had less activity against the isogenic strain, D21, with wildtype LpxC activity.
DISCUSSION AND CONCLUSION
We have approached the problem of novel antibiotic discovery by seeking a screening platform that allows interrogation of LpxC in a novel way. LpxC inhibitors have been identified, and these compounds have been shown to exhibit biological activity in preclinical studies. However, LpxC inhibitors have yet to reach clinical use, suggesting that compounds with improved characteristics are still required. We chose mass spectrometry, a label-free methodology, to evaluate the interaction of the native ligand with the native target. This technology allows interrogation of the full complement of interactions between ligand and target, free from the potential artifacts generated when nonnative, attenuated, or chemically modified ligands are used. 17, 18 This method of identifying specific molecules based on ion molecular weight has successfully identified library compounds that bind to a defined biomolecular target. 19 We have relied on a high-throughput sampling instrument designed to allow rapid compound purification, injection, and data analysis of a designated substrate and product ion from an enzymatic reaction mixture. 20 The use of mass spectrometry as the ultimate assay readout allowed relatively rapid development of an assay using the native LpxC substrate, without the requirement to engineer a compatible fluorogenic or antigenic peptide tag. We show that our screening assay shows linear response to increasing enzyme and increasing incubation (Fig. 4A) , a substrate K m comparable with literature values derived from experiments using a lowthroughput methodology (Fig. 4B) , and sensitivity to a known LpxC inhibitor (Fig. 4C ). 2 Analysis of 4 replicate DMSO test plates on 4 separate days generated an average assay Z' factor of 0.75, suggesting the assay is robust and plate variance insignificant. We conclude that the assay protocol would support a full library screening campaign.
The RapidFire technology allows rapid purification and injection of mass spectrometry compatible samples from quenched enzyme reactions. The analysis is sequential; each well of the 384-well plate is analyzed independently. This results in a slow throughput relative to assay systems using simultaneous reading of all wells in an assay plate. We improved the throughput of the screening campaign by analyzing the compound library as orthogonal mixtures of 8 compounds each. The use of mixtures decreases the number of plates required for the entire campaign, and the use of orthogonal mixtures allows each compound to be characterized twice, decreasing the occurrence of false positives. 14 Mixture screening can be problematic, especially in cases where an assay is sensitive to the increased organic compound concentrations present in the mixtures. Compound mixtures have been observed to generate non specific false positives, 21 although these can be eliminated upon single-compound confirmation testing. Orthogonal mixture screening does not appear inherently prone to generating false negatives, as determined by an analysis of a 26,400-member validation library for inhibitors of a CXCR3 ligand-receptor binding assay. 22 In our situation, use of a mass spectrometry-based assay eliminates false negatives observed when a fluorescence-based assay is attempted with mixtures containing one or more highly fluorescent test compounds. 23 Recently, Motlekar and coworkers 24 screened a 64,000-member compound library for cysteine and serine protease inhibitors in orthogonal mixtures of 10 compounds per well-all inhibitors identified by single-compound screening were also identified using orthogonal mixture screening. Use of mixture screening in mass spectrometry platforms could result in ion suppression, a property that results in lower overall signal within that well. As this is expected to affect both analytes similarly, our normalization protocol minimizes any effect of ion suppression, which is normalized out of the calculation. We found that orthogonal mixture screening resulted in a robust, well-behaved mass spectrometry-based screen (Fig.  6) with a median Z' factor of 0.76. The screen resulted in the identification of a number of potential LpxC inhibitors.
To document the interaction of these inhibitors with LpxC, we tested the ability of selected hit compounds to protect purified LpxC from thermal denaturation. 13 The technology tests the interaction of the test compound with target in the presence of a fluorescent reporter, an environmentally sensitive dye used to detect hydrophobic surfaces exposed as the target protein melts. We used this assay to characterize LpxC inhibitors with varying apparent potencies. Table 1 shows that the K d values calculated from the compound-dependent alteration in thermal denaturation compare favorably with the observed enzymatic inhibitor potencies. These results confirm that high-throughput mass spectrometry is capable of identifying valid LpxC inhibitors from complex compound mixtures present in orthogonal compound mixtures.
We finally sought to determine whether compounds identified in this manner exhibited biological activity. For this analysis, the selected LpxC inhibitors were tested for activity against 2 bacterial strains: E. coli D22 contains an lpxC mutation that renders the strain hypersensitive to antibacterial agents, whereas E. coli D21 is isogenic with a nonmutant lpxC gene. Table 1 shows that 5 of the 6 compounds demonstrated an ability to inhibit growth of E. coli D22, with MIC ranging from 2.5 to 10 mg/mL. The compounds had less activity against E. coli D21. Enhanced susceptibility of the D22 strain may be due to outer-membrane permeability defects of that strain, which cause general hypersensitivity to antibacterial agents. 16 Alternatively, hypersensitivity may be due to a mode of action involving LpxC.
We conclude that high-throughput mass spectrometry has proved to be a robust screening system, allowing the use of a complex native ligand to interrogate a large compound library as orthogonal mixtures. The campaign yields compounds that can be shown to stabilize target protein to thermal denaturation, yielding approximate K d values that correspond favorably to the IC 50 values obtained using quantitative mass spectrometry. Finally, selected compounds demonstrate significant bioactivity in standard cell-based antimicrobial activity assays. Development of novel LpxC inhibitors may provide a valuable new tool in the battle against antibiotic-resistant microorganisms.
